Literature DB >> 35790683

Serum fibrinogen-like protein 1 as a novel biomarker in polycystic ovary syndrome: a case-control study.

Y Zhang1, D Dilimulati1, D Chen2, M Cai1, H You1, H Sun1, X Gao3, X Shao4, M Zhang5, S Qu1.   

Abstract

PURPOSE: To investigate the relationship between fibrinogen-like protein 1 (FGL-1) concentrations and various metabolic characteristics in patients with polycystic ovary syndrome (PCOS) and explore whether FGL-1 could be a predictive biomarker for PCOS.
METHODS: This case-control study included 136 patients with PCOS and 34 normal controls recruited in the Department of Endocrinology and Metabolism, Shanghai Tenth People's Hospital between May 2017 and June 2021. Anthropometric characteristics, metabolic parameters, and reproductive hormones were collected. Serum FGL-1 measurement was conducted using enzyme-linked immunosorbent assay (ELISA) kits.
RESULTS: Serum FGL-1 concentrations were higher in patients with PCOS than in control subjects in body mass index (BMI) subgroups, insulin resistance (IR) subgroups, and hepatic function subgroups, respectively. Serum FGL-1 concentrations were significantly associated with BMI, glycosylated hemoglobin A1c (HbA1c), fasting plasma glucose (FPG), homeostasis model assessment of insulin resistance (HOMA-IR), alanine aminotransferase (ALT), aspartate aminotransferase (AST), high-density lipoprotein cholesterol (HDL-c), and serum uric acid (SUA) in all individuals. The receiver operating characteristic (ROC) curve analysis revealed that the best cutoff value for FGL-1 levels to predict PCOS was 21.02 ng/ml with a sensitivity of 74.3% and a specificity of 70.6%. Both univariate and multiple logistic regressions indicated that the odds ratio (OR) for PCOS significantly increased in the subjects with high levels of FGL-1.
CONCLUSION: In our study, FGL-1 was associated with serum aminotransferase and various metabolic indexes. Moreover, the high risk of PCOS was independently associated with the increased FGL-1 levels, which suggested that FGL-1 could be a predictive biomarker for PCOS.
© 2022. The Author(s), under exclusive licence to Italian Society of Endocrinology (SIE).

Entities:  

Keywords:  Aminotransferase; Fibrinogen-like protein 1 (FGL-1); Insulin resistance (IR); Obesity; Polycystic ovary syndrome (PCOS)

Mesh:

Substances:

Year:  2022        PMID: 35790683     DOI: 10.1007/s40618-022-01844-0

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   5.467


  25 in total

1.  Molecular cloning and functional expression analysis of a cDNA for human hepassocin, a liver-specific protein with hepatocyte mitogenic activity.

Authors:  H Hara; H Yoshimura; S Uchida; Y Toyoda; M Aoki; Y Sakai; S Morimoto; K Shiokawa
Journal:  Biochim Biophys Acta       Date:  2001-07-30

Review 2.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 3.  Polycystic ovary syndrome: a common hormonal condition with major metabolic sequelae that physicians should know about.

Authors:  S Shorakae; J Boyle; H Teede
Journal:  Intern Med J       Date:  2014-08       Impact factor: 2.048

Review 4.  Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment.

Authors:  Héctor F Escobar-Morreale
Journal:  Nat Rev Endocrinol       Date:  2018-03-23       Impact factor: 43.330

Review 5.  Metabolic risk in PCOS: phenotype and adiposity impact.

Authors:  Lisa J Moran; Robert J Norman; Helena J Teede
Journal:  Trends Endocrinol Metab       Date:  2015-01-12       Impact factor: 12.015

6.  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.

Authors:  D R Matthews; J P Hosker; A S Rudenski; B A Naylor; D F Treacher; R C Turner
Journal:  Diabetologia       Date:  1985-07       Impact factor: 10.122

7.  Discovery of a role of the novel hepatokine, hepassocin, in obesity.

Authors:  Ru-Lai Huang; Chung-Hao Li; Ye-Fong Du; Kai-Pi Cheng; Ching-Han Lin; Che-Yuan Hu; Jin Shang Wu; Chih-Jen Chang; Hung-Tsung Wu; Horng-Yih Ou
Journal:  Biofactors       Date:  2019-10-06       Impact factor: 6.113

8.  A novel hepatokine, HFREP1, plays a crucial role in the development of insulin resistance and type 2 diabetes.

Authors:  Hung-Tsung Wu; Horng-Yih Ou; Hao-Chang Hung; Yu-Chu Su; Feng-Hwa Lu; Jin-Shang Wu; Yi-Ching Yang; Chao-Liang Wu; Chih-Jen Chang
Journal:  Diabetologia       Date:  2016-05-25       Impact factor: 10.122

9.  Targeting fibrinogen-like protein 1 is a novel therapeutic strategy to combat obesity.

Authors:  Hung-Tsung Wu; Szu-Chi Chen; Kang-Chih Fan; Chun-Heng Kuo; Shin-Yu Lin; Shu-Huei Wang; Chih-Jen Chang; Hung-Yuan Li
Journal:  FASEB J       Date:  2019-12-27       Impact factor: 5.191

10.  Targeted deletion of fibrinogen like protein 1 reveals a novel role in energy substrate utilization.

Authors:  Valeriy Demchev; Geraldine Malana; Divya Vangala; Janis Stoll; Anal Desai; Hye Won Kang; Yingxia Li; Hamed Nayeb-Hashemi; Michele Niepel; David E Cohen; Chinweike Ukomadu
Journal:  PLoS One       Date:  2013-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.